HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $76,711,558 | +5.1% | 2,008,156 | -0.7% | 0.02% | +7.1% |
| Q2 2023 | $72,977,257 | -5.6% | 2,023,212 | -0.0% | 0.01% | -6.7% |
| Q1 2023 | $77,292,358 | -35.0% | 2,023,890 | -3.1% | 0.02% | -40.0% |
| Q4 2022 | $118,855,111 | +41.9% | 2,088,842 | -1.4% | 0.02% | +31.6% |
| Q3 2022 | $83,750,000 | -11.6% | 2,118,122 | -1.7% | 0.02% | -5.0% |
| Q2 2022 | $94,773,000 | +5.9% | 2,153,942 | -4.0% | 0.02% | +25.0% |
| Q1 2022 | $89,491,000 | -3.3% | 2,244,001 | -2.5% | 0.02% | +6.7% |
| Q4 2021 | $92,522,000 | -3.0% | 2,300,973 | -1.8% | 0.02% | -11.8% |
| Q3 2021 | $95,335,000 | -9.7% | 2,343,533 | +0.8% | 0.02% | -10.5% |
| Q2 2021 | $105,605,000 | +13.1% | 2,325,587 | +3.8% | 0.02% | +11.8% |
| Q1 2021 | $93,397,000 | -2.5% | 2,240,279 | -0.1% | 0.02% | -10.5% |
| Q4 2020 | $95,825,000 | +81.6% | 2,243,596 | +11.7% | 0.02% | +58.3% |
| Q3 2020 | $52,768,000 | -5.0% | 2,007,905 | -3.1% | 0.01% | -7.7% |
| Q2 2020 | $55,531,000 | +60.7% | 2,071,305 | +7.8% | 0.01% | +30.0% |
| Q1 2020 | $34,554,000 | -1.5% | 1,920,758 | -3.0% | 0.01% | +25.0% |
| Q4 2019 | $35,093,000 | +12.8% | 1,979,344 | -1.3% | 0.01% | +14.3% |
| Q3 2019 | $31,108,000 | +1.1% | 2,005,625 | +12.0% | 0.01% | 0.0% |
| Q2 2019 | $30,760,000 | +7.2% | 1,790,475 | +0.5% | 0.01% | 0.0% |
| Q1 2019 | $28,692,000 | +10.9% | 1,782,098 | +0.8% | 0.01% | 0.0% |
| Q4 2018 | $25,872,000 | -21.8% | 1,768,452 | -2.9% | 0.01% | -12.5% |
| Q3 2018 | $33,097,000 | +6.6% | 1,821,526 | -1.1% | 0.01% | 0.0% |
| Q2 2018 | $31,059,000 | -4.4% | 1,841,060 | +11.1% | 0.01% | 0.0% |
| Q1 2018 | $32,472,000 | -2.9% | 1,657,580 | +0.4% | 0.01% | 0.0% |
| Q4 2017 | $33,454,000 | +12.6% | 1,651,195 | -3.4% | 0.01% | 0.0% |
| Q3 2017 | $29,704,000 | +55.2% | 1,710,107 | +14.6% | 0.01% | +60.0% |
| Q2 2017 | $19,138,000 | +6.6% | 1,492,747 | +7.7% | 0.01% | 0.0% |
| Q1 2017 | $17,955,000 | +32.1% | 1,385,414 | +0.7% | 0.01% | +25.0% |
| Q4 2016 | $13,589,000 | -14.1% | 1,375,360 | +5.1% | 0.00% | -20.0% |
| Q3 2016 | $15,813,000 | +39.8% | 1,309,023 | -0.2% | 0.01% | +25.0% |
| Q2 2016 | $11,315,000 | -6.2% | 1,311,180 | +2.9% | 0.00% | 0.0% |
| Q1 2016 | $12,068,000 | -44.4% | 1,273,797 | +1.7% | 0.00% | -42.9% |
| Q4 2015 | $21,702,000 | +32.0% | 1,252,282 | +2.3% | 0.01% | +40.0% |
| Q3 2015 | $16,446,000 | -38.1% | 1,224,455 | +4.1% | 0.01% | -37.5% |
| Q2 2015 | $26,560,000 | +63.4% | 1,176,272 | +3.3% | 0.01% | +60.0% |
| Q1 2015 | $16,254,000 | +50.4% | 1,138,171 | +1.6% | 0.01% | +66.7% |
| Q4 2014 | $10,809,000 | +2.0% | 1,120,058 | -3.9% | 0.00% | 0.0% |
| Q3 2014 | $10,601,000 | -9.5% | 1,165,040 | -1.8% | 0.00% | -25.0% |
| Q2 2014 | $11,720,000 | -27.6% | 1,186,177 | -7.0% | 0.00% | -20.0% |
| Q1 2014 | $16,198,000 | -15.8% | 1,274,963 | -0.7% | 0.01% | -16.7% |
| Q4 2013 | $19,240,000 | +36.7% | 1,283,480 | +0.7% | 0.01% | +20.0% |
| Q3 2013 | $14,070,000 | +37.5% | 1,274,416 | -1.0% | 0.01% | +25.0% |
| Q2 2013 | $10,231,000 | – | 1,286,898 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |